Brought to you by 
YM merges with Cytopia in $Cdn12mm deal
25 Feb 2021
Executive Summary
YM Biosciences (therapeutics for cancer and pain) has agreed to merge with Australia's Cytopia (oncology focused, with other treatments for cardiovascular, autoimmune, and inflammatory conditions). YM will issue one of its common shares for every 11.737 Cytopia shares, or an aggregate of 7.2mm shares valued at $Cdn12mm ($11.1mm). The per share ratio of $Cdn0.17 represents a 55% premium.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
YM merges with Cytopia in $Cdn12mm deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice